SHC

AI Memo

Sotera Health

As of 2026-11-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-11-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Delivery against reaffirmed FY2026 outlook • 2027-02-28

Base target: $16 / p=45% prob

Biggest risk

The beat did not translate into higher FY2026 guidance. Management described European medical-device demand weakness extending into Q4; Nordion revenue fell on Co-60 harvest timing. JPMorgan had downgraded SHC before the print, from Neutral to Underweight, cutting its target from $18 to $17. No verified post-print target or estimate revisions were found. Call transcript JPMorgan action

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Q3 adjusted EPS of $0.29 exceeded the approximately $0.27 consensus, and revenue of $324.9 million exceeded the approximately $319.8 million consensus. Sterigenics and Nelson Labs grew, operating cash flow was $111 million, and net leverage improved to 2.9x. A stabilization in European demand could restore confidence. Company release Consensus comparison

Research note

Recommendation

—

Confidence

medium

As of

2026-11-04

Base target

$16

p=45%

Bull target

$20

p=25%

Bear target

$12

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

European medical-device demand weakness
Sterilization mix and cash-flow durability
Q3 adjusted EPS of $0.29 exceeded the approximately $0.27 consensus, and revenue of $324.9 million exceeded the approximately $319.8 million consensus.

BearKey bullets

Ethylene-oxide litigation, regulation, and EO or Co-60 supply disruptions remain disclosed risks.
Company release
European medical-device customer softness could persist beyond Q4; management has not provided a quantified 2027 demand outlook.

WatchKey bullets

Delivery against reaffirmed FY2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $16 (p=45%)

Target spread vs base: +25% / -25%

Scenario probabilities

Bull Target: $20 (p=25%)Base Target: $16 (p=45%)Bear Target: $12 (p=30%)

Commentary

SHC closed November 3 at the packet's $16.03 anchor, about 9.6% below the prior $17.74 close, despite the modest earnings beat. Historical prices Coverage linked the selloff to European demand concerns and unchanged guidance, but that attribution is interpretive. Market coverage No verified post-print analyst revision is available. The sentiment numeric fields are unavailable-data placeholders, not measured neutral readings. The deterministic prior shifted from neutral to negative, supporting caution rather than extrapolation from the beat.

As of 2026-11-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

European medical-device demand weakness
Sterilization mix and cash-flow durability

Scenarios

Bull Target (Scenario probability)

$20 / p=25% prob

Base Target (Scenario probability)

$16 / p=45% prob

Bear Target (Scenario probability)

$12 / p=30% prob

Analysis 2026-11-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-02-28
Delivery against reaffirmed FY2026 outlook
Despite Q3 revenue growth of 4.4% and adjusted EPS of $0.29, Sotera reaffirmed—not raised—FY2026 constant-currency revenue growth of 5.25%–6.75% and adjusted EBITDA growth of 5.75%–7.25%. Delivery against those ranges is the next substantive test; the date is an estimate, not an announced release date. [#8-K-2026-11-03] [#SEC-8K-2026-11-03] Company release
Prob 55.00% • Move 7.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

European medical-device demand weakness
2026-12-31
On the Q3 call, management said customer softness that began in Q3 persisted into Q4, primarily in Europe, while U.S. demand was relatively stable. Whether that weakness deepens is the immediate downside test. Call transcript
Prob 60% • Move -6% • Priced-in 55%

Long-term Catalysts

Months to a year

Sterilization mix and cash-flow durability
2027-06-30
Q3 constant-currency revenue rose 8.2% at Sterigenics and 9.2% at Nelson Labs, but fell 11.5% at Nordion on expected Co-60 harvest timing. Sustained segment growth, normalization of harvest timing, and conversion of the planned capital-spending step-down into cash flow remain unproven. [#SEC-8K-2026-11-03] Company release
Prob 50% • Move 8% • Priced-in 45%

Risks

Ethylene-oxide litigation, regulation, and EO or Co-60 supply disruptions remain disclosed risks. Company release
European medical-device customer softness could persist beyond Q4; management has not provided a quantified 2027 demand outlook. Call transcript
Nordion's Co-60 harvest schedules create quarterly volume and mix volatility; Nelson Labs' Q3 segment income grew more slowly than revenue. [#SEC-8K-2026-11-03]
The company reported $2.2 billion of debt at September 30, 2026; leverage remains consequential despite improvement to 2.9x. Company release

Peers

Symbol	Summary
CRL	Charles River has microbial and biologics testing exposure relevant to Nelson Labs, but its broader research and manufacturing portfolio makes it only a partial comparison. Charles River
STE	STERIS is the closest operating comparison identified: its Applied Sterilization Technologies business provides contract sterilization and testing. Company-wide valuation is still imperfect because STERIS has other businesses. STERIS

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-11-04

Loading AI feed…

Symbol

Summary

CRL

Charles River has microbial and biologics testing exposure relevant to Nelson Labs, but its broader research and manufacturing portfolio makes it only a partial comparison. Charles River

STE

STERIS is the closest operating comparison identified: its Applied Sterilization Technologies business provides contract sterilization and testing. Company-wide valuation is still imperfect because STERIS has other businesses. STERIS